Press

MedGenome to present its tumor microenvironment analysis results at the AACR Cancer Immunotherapy Conference in New York

The remarkable success of checkpoint control inhibitors in treating a variety of different cancers has necessitated a deeper assessment of the tumor and its microenvironment at the genetic and phenotypic level. Data from recent clinical trials has unequivocally established that the tumor microenvironment significantly impacts the efficacy of immune-oncology drugs.

Considering Genomic Research?

    Fields marked in * is mandatory to fill
     
     
     

    2024 © MedGenome • All Rights Reserved
    Request a Quote